Our real-life report of TPO-RA off-label use, even though on a small number of patients, highlights their efficacy and safety in difficult-to-manage thrombocytopenia forms, including post-transplant ITP and cases secondary to MDS and lymphoproliferative syndromes. This evidence concerns the gene TPO and lymphoproliferative syndrome.